Indivior PLC Reinvents Leadership with Nasdaq Listing Move

Indivior PLC, a pharmaceutical company focused on opioid addiction treatment, has undergone a leadership overhaul and moved its primary listing from the London Stock Exchange to Nasdaq. The company has demonstrated strong growth and resilience, recently reaching a 52-week stock high. Indivior has also presented new findings at the 2025 CPDD meeting and received FDA approval for updated labeling for its flagship product SUBLOCADE.

Indivior PLC, a pharmaceutical company specializing in opioid addiction treatment, has recently undergone significant changes in leadership and operational structure. The company's strategic overhaul includes the appointment of Joe Ciaffoni as CEO, Patrick Barry as Chief Commercial Officer, and Tony Kingsley as a board member. These appointments reflect a focused effort to boost performance and align leadership with U.S. market priorities [1].

Indivior PLC's flagship product, SUBLOCADE, a monthly buprenorphine injection, has been the cornerstone of the company's growth. In 2025, the company presented new findings at the 2025 CPDD meeting, demonstrating that higher buprenorphine exposure may improve treatment outcomes in patients with high fentanyl use. This development is particularly critical given the ongoing fentanyl crisis. Additionally, the FDA has approved updated labeling for SUBLOCADE, further expanding its clinical utility [1].

In line with its strategic realignment, Indivior PLC announced plans to shift its primary listing from the London Stock Exchange to Nasdaq. This move aims to enhance visibility and investor engagement in the American market [1]. The company has shown resilience and strong growth, recently reaching a 52-week stock high.

Emergent BioSolutions, another key player in the opioid treatment space, has commended the U.S. House of Representatives for implementing over-the-counter (OTC) naloxone availability at all AED locations in its buildings. This initiative, led by Representative Buddy Carter (R-GA), aims to provide immediate access to life-saving treatment for potential opioid overdoses. Emergent BioSolutions, which offers NARCAN® Nasal Spray, the first OTC opioid overdose reversal treatment, has distributed over 85 million doses across the U.S. and Canada since 2016 [2].

These developments underscore the ongoing efforts to address the opioid crisis and highlight the importance of innovative treatments and accessible solutions.

References:
[1] https://finance.yahoo.com/news/indivior-plc-indv-reinvents-leadership-140609777.html
[2] https://www.stocktitan.net/news/EBS/emergent-applauds-availability-of-over-the-counter-naloxone-in-u-s-gt3wmimjczyu.html